Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login
Market Place

Information, Expiry & Status of FDA Orange Book Patents covering Prestwick3_001058

Client Email

Product

Prestwick3_001058
US Patents

PharmaCompass Sponsored Ads

Contact Supplier

FAMAR CDMO- From early development to commercial manufacturing.

Contact Supplier

xyz-pharma-m-2024-09-09

Contact Supplier

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Contact Supplier

Veranova: A CDMO that manages complexity with confidence.

Contact Supplier

xyz-pharma-m-2024-09-09

Contact Supplier

Prestwick3_001058

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

25 API Suppliers, 8 USDMF, 8 EU WC, 3 KDMF, 7 NDC API, 21 Listed Suppliers, $ API Reference Price

25 API Suppliers
8 USDMF
8 EU WC
3 KDMF
7 NDC API
21 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

32 Drugs in Development

32 Drugs in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

API Reference Price
API Exports
API Imports
FDF Exports
FDF Imports

INTERMEDIATES

8 API Suppliers

8 API Suppliers

FINISHED DOSAGE FORMULATIONS

425 FDF Dossiers, 29 FDA Orange Book, 143 Europe, 26 Canada, 88 Australia, 45 South Africa, 94 Listed Dossiers

425 FDF Dossiers
29 FDA Orange Book
143 Europe
26 Canada
88 Australia
45 South Africa
94 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, ORALLY DISINTEGRATING;ORAL - 4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, ORALLY DISINTEGRATING;ORAL - 8MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM;ORAL - 4MG, FILM;ORAL - 8MG

TABLET, ORALLY DISINTEGRATING;ORAL - 4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, ORALLY DISINTEGRATING;ORAL - 8MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
FILM;ORAL - 4MG
FILM;ORAL - 8MG

RELATED EXCIPIENT COMPANIES

1 Minakem, 6 Rochem International Inc, 22 SPI Pharma, 2 Seqens, 10 DKSH, 3 Jai Radhe Sales, 2 Pharm-RX Chemical, 4 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 16 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 4 ACG Worldwide, 9 Actylis, 2 Aeon Procare, 2 Alcedo Pharmachem, 10 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 17 BASF, 1 Bioplus Life Sciences, 11 Corel Pharma Chem, 7 DFE Pharma, 1 Doshion Polyscience, 1 Finar, 11 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 37 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 16 Microlex e.U, 1 Nanjing Bold Chemical, 1 NEWEDGE Overseas, 2 Nomisma Healthcare, 2 Novo Excipients, 4 Pharmatrans-Sanaq, 6 Pluviaendo, 5 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 29 Roquette, 13 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 5 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

90 Fillers, Diluents & Binders, 50 Direct Compression, 47 Coating Systems & Additives, 45 Disintegrants & Superdisintegrants, 32 Thickeners and Stabilizers, 27 Controlled & Modified Release, 26 Taste Masking, 25 Granulation, 24 Lubricants & Glidants, 23 Chewable & Orodispersible Aids, 19 Co-Processed Excipients, 19 Solubilizers, 18 Film Formers & Plasticizers, 16 Parenteral, 12 Topical, 9 Empty Capsules, 8 API Stability Enhancers, 7 Emulsifying Agents, 6 Rheology Modifiers, 4 Vegetarian Capsules, 4 Coloring Agents, 2 Surfactant & Foaming Agents, 1 Soft Gelatin

90 Fillers, Diluents & Binders
50 Direct Compression
47 Coating Systems & Additives
45 Disintegrants & Superdisintegrants
32 Thickeners and Stabilizers
27 Controlled & Modified Release
26 Taste Masking
25 Granulation
24 Lubricants & Glidants
23 Chewable & Orodispersible Aids
19 Co-Processed Excipients
19 Solubilizers
18 Film Formers & Plasticizers
16 Parenteral
12 Topical
9 Empty Capsules
8 API Stability Enhancers
7 Emulsifying Agents
6 Rheology Modifiers
4 Vegetarian Capsules
4 Coloring Agents
2 Surfactant & Foaming Agents
1 Soft Gelatin

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 30 NEWS #PharmaBuzz

1 DATA COMPILATION #PharmaFlow
30 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

130 Finished Drug Prices

130 Finished Drug Prices

MARKET PLACE

14 APIs, 23 FDF Dossiers

14 APIs
23 FDF Dossiers

PATENTS & EXCLUSIVITIES

4 US Patents, 2 Health Canada Patents

4 US Patents
2 Health Canada Patents

REF. STANDARDS & IMPURITIES

4 USP, 9 Others

4 USP
9 Others

ANALYTICAL

2 BioAnalytical Methods

2 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 1,225 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

4 All

01 4AQUESTIVE

filter Patent Number Reset all filters

4 All

01 28580830

02 29095577

filter API Patent Reset all filters

4 All

01 4Blank

filter FDF Patent Reset all filters

4 All

01 4Y

filter Expiration Date Reset all filters

4 All

01 22029-11-23

02 22030-07-13

Athena Ondansetron

US Patents
Health Canada Patents

Product Main Page

01

AQUESTIVE

Boulder Peptide 2024

Not Confirmed

AQUESTIVE

Boulder Peptide 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-07-13

ONDANSETRON

US Patent Number : 9095577

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 22524

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-07-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

AQUESTIVE

Boulder Peptide 2024

Not Confirmed

AQUESTIVE

Boulder Peptide 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-11-23

ONDANSETRON

US Patent Number : 8580830

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 22524

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-11-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

AQUESTIVE

Boulder Peptide 2024

Not Confirmed

AQUESTIVE

Boulder Peptide 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-07-13

ONDANSETRON

US Patent Number : 9095577

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 22524

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-07-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

AQUESTIVE

Boulder Peptide 2024

Not Confirmed

AQUESTIVE

Boulder Peptide 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-11-23

ONDANSETRON

US Patent Number : 8580830

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 22524

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-11-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?